Ellume is a digital diagnostics company that develops and commercializes accurate, connected products for healthcare professionals and consumers.

We focus on the detection of common illnesses that affect the global population. Our products differ from conventional diagnostics through a digitally enabled link to treatment.


We have developed a new biosensor technology which features unique optoelectronics and biologics. Our novel quantum dot platform makes this technology usable for the detection of many illnesses.

Recent News

Ellume announces another global partnership – this time with QIAGEN on the detection of tuberculosis

  • Posted by Ellume
  • On January 8, 2019
Highlights Australia’s Ellume Limited has partnered with QIAGEN N.V. to bring the next generation of latent TB testing to low-resource, high-burden countries The deal includes the licensing of Ellume technologies and a USD $15M minority investment by QIAGEN in Ellume Limited This announcement builds on the recent announcement of a global partnership with GlaxoSmithKline announced […]
Read More

Ellume spreads global wings with GSK deal

  • Posted by Ellume
  • On December 11, 2018
Brisbane medical diagnostics company Ellume has signed a significant deal with pharmaceutical giant GSK for digital consumer products, ahead of a potential market listing. Ellume founder and managing directory Sean Parsons said the global deal was the biggest of its kind in Australia.
Read More